Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

83.17 +1.68 (+2.06%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

Today 2:15 EST

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

December 02, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

December 01, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

November 17, 2025

From Biogen Inc.

Via GlobeNewswire

Biogen Completes Acquisition of Alcyone Therapeutics

November 14, 2025

From Biogen Inc.

Via GlobeNewswire

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

November 14, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

November 13, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at upcoming investor conferences

November 12, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

November 11, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

November 08, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

November 06, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis reports third quarter 2025 financial results and highlights progress on key programs

October 29, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

October 27, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

October 23, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

October 21, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to hold third quarter 2025 financial results webcast

October 16, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

October 07, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

September 23, 2025

From Biogen Inc.

Via GlobeNewswire

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

September 22, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

September 19, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

September 18, 2025

From Biogen Inc.

Via GlobeNewswire

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

September 12, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

September 09, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to host investors and analysts for Innovation Day 2025

September 08, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at upcoming investor conferences

September 02, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

September 02, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

August 21, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis reports second quarter 2025 financial results and highlights progress on key programs

July 30, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

July 25, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.